President and CEO, BioMarker Strategies, LLC
Jerry Parrott joined BioMarker Strategies as CEO in October 2013. He also serves as Chairman, Maryland Health Care Product Development Corporation. Jerry served Human Genome Sciences as VP, Corporate Affairs and Public Policy from 2001 until its 2012 acquisition by GlaxoSmithKline. He formerly held senior positions with Bristol-Myers Squibb, American Hospital Supply and Walgreen Company. From 1995-2001, Jerry’s consulting clients included HGS, Bristol-Myers Squibb, Ciba-Geigy, Genentech, HealthCare Ventures, Hoffmann-La Roche and Wyeth. He helped take public 3-Dimensional Pharmaceuticals, acquired by Johnson & Johnson, and InforMax, acquired by Invitrogen. Jerry is a Director of Noxilizer, MdBio and Tech Council of Maryland.
Functional Profiling to Guide Cancer Drug Development and Treatment Selection
A discussion of the SnapPath® Cancer Diagnostics System, which generates purified populations of live solid tumor cells from fresh unfixed samples, and preserves molecular integrity for standardized ex vivo exposure to targeted therapeutics. Resulting biomarker tests help identify and understand mechanisms of acquired resistance and better predict individual response.